Top 2 Index Funds to Beat the S&P 500 Over the Next 5 Years, According to Wall Street

S&P 600 returned to positive year-over-year earnings growth in Q2 2025 and is forecast to deliver higher earnings growth than the S&P 500 by late 2026; small-cap P/E is cited as >30% below the large-cap index. The piece recommends iShares Core S&P Small-Cap ETF (IJR, expense ratio 0.06%) and Vanguard Mid-Cap ETF (VO, expense ratio 0.03%) as low-cost ways to gain exposure to expected small/mid-cap outperformance. Vanguard Mid-Cap’s sector mix is more diversified (Industrials ~20%; Consumer Discretionary, Financials, Technology ~13–15% each), positioning it as less concentrated than the S&P 500 dominated by mega-cap tech/AI names.

Analysis

Rotation out of concentrated growth into smaller, more cyclically exposed issuers favors companies and suppliers tied to domestic demand, capex, and regional banking flows. Mid-cap industrials and domestic-focused consumer names should see outsized operating leverage if capex and hiring remain intact; second-order winners include test-equipment vendors, substrate/packaging suppliers and regional logistics providers that scale with reshoring activity. Smaller banks and non-bank lenders that expand commercial lending to mid-market firms will capture spread expansion faster than large diversified lenders, amplifying earnings revisions in that sector.

Key risks live on the macro-financial axis: a faster-than-expected Fed pivot (disinflation surprise) would re-price long-duration growth assets back to favor, while tighter credit or a sequenced slowdown in consumer credit would disproportionately hit small/mid caps with higher short-term leverage. Earnings revisions that underpin a durable re-rating will take quarters, not days — look for consistent positive guidance revisions across two consecutive quarters (6–9 months) before assuming a full regime change. Liquidity-driven reversals are plausible within weeks if passive flows rotate back to mega-cap ETFs or if market breadth deteriorates sharply.

From a tactical perspective, crowding is the obvious counterparty risk. If multiple allocators pursue the same small/mid cap lever (cheap P/E + earnings catch-up), the first negative macro surprise will produce a larger-than-normal drawdown as stop-lists unwind. Conversely, selective exposure to industrial supply-chains and regional financials provides an asymmetric hedge versus a pure small-cap beta play because those names have idiosyncratic catalysts (contracts, syndicated loan growth, capex awards) that can re-rate independently of broad sentiment.

A prudent path is to scale exposure over 6–12 months on confirmed earnings beats and guidance upgrades while retaining convexity via options to limit capital-at-risk. Monitor three triggers closely: (1) sequential earnings revision breadth across the Russell 2000/CRSP mid cap universe; (2) 3‑month change in regional bank loan growth vs national peers; (3) any tariff policy shifts or public capex awards that reallocate corporate supply chains domestically.

Key Decisions for Investors

• Pair trade (12–24 months): Long VO (Vanguard Mid-Cap ETF) 1.0% notional / Short QQQ 1.0% notional to express mid‑cap / small‑cap tilt vs mega‑cap concentration. Target relative outperformance +18–25% over 12–24 months; cut the pair if QQQ outperforms by >12% in 60 days (liquidity stop).
• Convex long (12–36 months): Buy IJR Jan 2028 call spread (buy LEAP call, sell higher strike LEAP call) sized at 0.5–1.0% portfolio risk to limit premium spent. Expect 2–4x payoff if small/mid cap earnings breadth improves; max loss = premium ~1% notional.
• Macro hedge (3 months rolling): Buy 3‑month ATM puts on NVDA equal to 0.25–0.5% notional as insurance against a tech-led liquidity reversal that would derail rotation. Cost is insurance; payoff is large tail protection if mega‑cap derates quickly.
• Thematic selective long (6–18 months): Allocate 0.5–1.0% to mid‑cap industrial suppliers and regional bank names with visible loan growth (replace broad small‑cap beta). Target absolute upside 20–30% on idiosyncratic wins (new contracts, syndicated deals); set single-name stop at -30% to limit balance-sheet risk.